Highly Galactosylated Anti-CD20 Rituximab, a Biobetter Antibody (CAT#: BioBet-GA-001ZP) Datasheet

Target
CD20
Isotype
Full Humanized Antibody
Description
Galactosylation of the IgG Fc region has been observed to modestly enhance C1q binding and ADCC in vitro in therapeutic antibodies. The Highly Galactosylated Anti-CD20 Rituximab, a Biobetter Antibody contains with a high level of galactosylation, and produced by the Fc engineering platform of Creative Biolabs.
Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter
Patent
The patent of rituximab was expired in 2016, and a number of biosimilars have been launched.
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
MS4A1
Full Name
membrane spanning 4-domains A1
Background
This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein.
Alternative Names
B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16
Gene ID
UniProt ID
Cellular Localization
Plasma membrane
Genecards
Ensembl
OMIM
Diseases associated with MS4A1 include Immunodeficiency, Common Variable, 5 and Common Variable Immunodeficiency.
Involvement in Disease
Its related pathways are Hematopoietic cell lineage and Hematopoietic Stem Cells and Lineage-specific Markers.
Related Pathways
b lymphocyte-specific membrane protein, which is involved in the regulation of cellular calcium influx necessary for the development, differentiation and activation of b lymphocytes (PubMed:3925015, PubMed:7684739, PubMed:12920111). After activation of b-cell receptor/BCR, it acts as a component of stored and operated calcium (SOC) channels to promote calcium influx (PubMed:7684739, PubMed:12920111, PubMed:18474602).
Function
Cancer antibody; Developmental Biology antibody; Immune System antibody; B cell Marker antibody; Immature B Cell Marker antibody; Inflammatory Cell Marker antibody; Tumor-infiltrating Lymphocyte Study antibody
Field of research
Phosphorylated. Might be functionally regulated by protein kinase(s).
Trade name
Rituxan®
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB00073 (BTD00014, BIOD00014)
CAS number
174722-31-7
Antibody Isotype
Full Humanized Antibody
Antibody Clone
Rituximab
Species Reactivity
Human
Description
Rituximab is a chimeric mouse / human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. It was first approved by the US FDA in 1997 as a single drug for patients with B-cell non-Hodgkin's lymphoma (NHL), but is now approved for multiple diseases. In 2018, the FDA approved Truxima, the first biosimilar drug similar to Rituxan (Rituximab)
Indication
Non-Hodgkin's Lymphoma (NHL)
Chronic Lymphocytic Leukemia (CLL)
Rheumatoid Arthritis (RA)
Granulomatosis with Polyangiitis (GPA)
Moderate to severe Pemphigus Vulgaris (PV) in adult patients
Synonyms
rituximab-abbs
rituximab-pvvr
UNII
4F4X42SYQ6

Similar to the parental antibody rituximab, glycoengineered ADCC-enhancement rituximab binds to the cell surface protein CD20 and enhances direct cell death and ADCC / ADCP effect. It tends to primarily affect malignant B cells with the highest CD20 levels.
There is evidence that when rituximab Fc binds to NK cell surface receptors, the success rate of killing cells reaches 80%. Therefore, the ADCC effect is the core mechanism by which rituximab works.

Rituximab was approved for medical use in 1997 to treat certain autoimmune diseases and cancer. By destroying CD20 that is present on the surface of B cells of the immune system, rituximab is mainly used to treat diseases characterized by excessive B cells, excessive B cell activity, or abnormal B cell function. It is also used for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis, etc.
Blood cancers
Rituximab is used to treat cancers of the white blood cell system, such as leukemia and lymphoma, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and the major lymphocyte subtype of Hodgkin's lymphoma.
Autoimmune diseases
There is evidence that rituximab is an effective treatment for rheumatoid arthritis. Rituximab has been widely used to treat a variety of other autoimmune diseases, including multiple sclerosis, systemic lupus erythematosus, chronic inflammatory demyelinating polyneuropathy, and autoimmune anemia.

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK